A 32-year-old male construction worker from Delhi presents with a 3-week history of productive cough, fever, and night sweats. Clinical examination reveals crackles in the right upper lobe. Chest X-ray shows cavitary lesion in the right upper lobe. Which investigation is most appropriate to confirm the diagnosis and assess drug susceptibility?

## Investigation of Choice for TB Confirmation with Drug Susceptibility Assessment **Key Point:** Per current WHO (2021) and NTEP (2023) guidelines, **GeneXpert MTB/RIF assay** is the recommended **first-line diagnostic test** for all presumptive TB cases. It simultaneously confirms *Mycobacterium tuberculosis* AND detects rifampicin resistance (the primary marker of MDR-TB) within ~2 hours. ### Why GeneXpert MTB/RIF Assay is Correct In a patient with clinical and radiological features strongly suggestive of pulmonary TB (3-week productive cough, fever, night sweats, cavitary lesion in right upper lobe), the most appropriate **initial** investigation to: 1. **Confirm the diagnosis** — GeneXpert detects MTB-specific DNA with ~98% sensitivity and ~99% specificity in smear-positive cases; ~67–80% in smear-negative cases 2. **Assess drug susceptibility** — detects rifampicin resistance (rpoB gene mutations), which serves as a surrogate marker for MDR-TB 3. **Guide immediate therapy** — results available in ~2 hours, enabling same-day treatment decisions **High-Yield (NTEP 2023 / WHO 2021):** - GeneXpert MTB/RIF is now the **universal first-line test** for all presumptive TB patients in India under NTEP - Replaces sputum smear microscopy as the initial diagnostic step - RIF resistance detected → initiate MDR-TB workup and second-line DST (via culture or line probe assay) ### Comparison of Investigations | Investigation | Sensitivity | Specificity | Time to Result | DST Capability | Current Role | |---|---|---|---|---|---| | **GeneXpert MTB/RIF** | 98% (smear+) | 99% | ~2 hours | Partial (RIF only) | **First-line: rapid diagnosis + RIF resistance** | | **Sputum smear (ZN)** | 60–80% | High | 1–2 days | No | Adjunct; no longer first-line | | **Sputum culture (LJ) + DST** | 95–100% | 100% | 2–8 weeks | Yes (comprehensive) | Gold standard for comprehensive DST; second-line after GeneXpert | | **TST** | 70–80% | 60–70% | 48–72 hours | No | Screening only; not diagnostic | ### Why Other Options Are Incorrect - **Option B (Smear microscopy only):** Cannot assess drug susceptibility; no longer recommended as the sole initial test per NTEP 2023. Fails to address the drug susceptibility component of the question. - **Option C (TST):** A screening tool for latent TB infection; cannot confirm active TB or assess drug resistance. Not appropriate for a symptomatic patient with cavitary disease. - **Option D (Culture + DST on LJ medium):** Although the gold standard for comprehensive DST, it takes 2–8 weeks for results. Per current NTEP 2023 and WHO 2021 guidelines, GeneXpert is the recommended **first-line** investigation for both diagnosis and initial drug susceptibility assessment. Culture with full DST is reserved as a follow-up when GeneXpert detects RIF resistance or when comprehensive second-line DST is needed. **Clinical Pearl:** When the question asks for the investigation to **both confirm diagnosis AND assess drug susceptibility** in a new presumptive TB case, GeneXpert MTB/RIF is the single best answer per current guidelines. The question stem does not specify a context where culture would be preferred over GeneXpert as the initial test (e.g., GeneXpert-negative but high clinical suspicion, or need for second-line DST). **Reference:** WHO Consolidated Guidelines on Tuberculosis, Module 3: Diagnosis (2021); NTEP Technical and Operational Guidelines for Tuberculosis Control in India (2023 update).